Navigation Links
XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
Date:8/28/2007

t must meet certain financial requirements and adhere to NASDAQ's corporate governance standards.

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development and commercialization of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating continued trading of the Company's ADRs on the NASDAQ Global Market, the potential transfer of trading to the NASDAQ Capital Market, the expected uninterrupted trading of the ADR, and the Company's ability to comply with NASDAQ Capital Market listing requirements, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Risk factors that could adversely affect our operations are identified from time to time in our reports filed with the Securities and Exchange Commission and the London Stock Exchange, including our annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2007. Any forward-looking statements set forth in this press release speak
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Lucigen receives $750K grant to boost biofuel yields
3. Medical College receives $1.4M cancer grant
4. Wisconsin biotech firm receives $107K NIH grant
5. InvivoSciences receives NIH grant for heart technology
6. Medical College receives $11 million grant to study high blood pressure
7. Madison business receives $115,000 of new state biofuels funding
8. Superior receives funds for technical training
9. UWM receives state funding for plastics research
10. GEs Centricity EHR receives federal certification
11. WHIE receives state eHealth Initiative contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 About POCT ... is performed outside a clinical laboratory. It helps ... administrating appropriate treatments and medication. POCT is gaining ... of lifestyle diseases such as diabetes, heart disease, ... POCT devices are standardized to minimize errors during ...
(Date:9/18/2014)... Ireland , September 18, 2014 ... and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has ... "Biocompatible Materials - Global Strategic Business ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes ... in US$ Million by the following ...
(Date:9/18/2014)... , Sept. 18, 2014 ... of the "Global N-acetylcysteine Industry Report 2014" ... The Global N-acetylcysteine Industry Report 2014 is a ... of the global N-acetylcysteine industry. The ... including definitions, classifications, applications and industry chain structure. ...
(Date:9/18/2014)... 2014  U.S. biotech company Kultevat has ... for technology developed by the Donald Danforth Plant ... including for applications in production of natural rubber in ... was developed under the direction of Roger Beachy ... president of the Danforth Plant Science Center, and is ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2Kultevat obtains license of gene switch technology 2
... Offers Both Built-in ... Controls, INDIANAPOLIS, Oct. 29 Roche Diagnostics, ... and optional, external,liquid controls to help non-waived clinics ... for patients taking,blood thinner medication. The handheld, ...
... Surfaces Prompts Horizon Business Group To Spin-Off ... ... Ill., Oct. 29 Due to fast-growing global,demand for specially ... the,performance, aesthetics and durability of metal products and surfaces,Horizon Business ...
... Cliniqa Corporation (San,Marcos, CA), a manufacturer of ... acquisition of the primary assets of Reagents ... owned subsidiary of Hemagen,Diagnostics, Inc. (Columbia, MD). ... focusing on clinical chemistry reagents, calibrators,and controls. ...
Cached Biology Technology:Roche Diagnostics Launches CoaguChek XS Plus System to Provide New PT/INR Point-of-Care Solution for Non-Waived Anticoagulation Services 2Roche Diagnostics Launches CoaguChek XS Plus System to Provide New PT/INR Point-of-Care Solution for Non-Waived Anticoagulation Services 3Roche Diagnostics Launches CoaguChek XS Plus System to Provide New PT/INR Point-of-Care Solution for Non-Waived Anticoagulation Services 4Sureshield Coatings Company Established to Market Industry-Leading Portfolio of Advanced Coatings for Metal Surfaces 2Sureshield Coatings Company Established to Market Industry-Leading Portfolio of Advanced Coatings for Metal Surfaces 3Cliniqa Corporation Completes Asset Acquisition of Reagents Applications, Inc. 2
(Date:9/18/2014)... The global cycles of carbon and nitrogen comprise ... human and environmental systems have caused imbalances and ... greenhouse gases (GHGs). Increased GHGs result in climate ... terrestrial ecosystems, oceans and the atmosphere. Understanding these ... exciting branch of environmental science during the past ...
(Date:9/18/2014)... up to 400 kilometres in search of a home, which ... Clownfish spend their entire adult lives under the protection of ... open ocean, says study co-author, Dr Hugo Harrison from the ... at James Cook University. , "In the past we haven,t ... rare glimpse into how far they can swim, crossing large ...
(Date:9/17/2014)... doctoral student have designed a device based on a ... and dew., The device could provide water in drought-stricken ... Cheng Luo, professor in the Mechanical & Aerospace Engineering ... College of Engineering department, published "Bioinspired Plate-Based Fog Collectors" ... Society) Applied Materials & Interfaces ...
Breaking Biology News(10 mins):Greenhouse gas research enters a new era 2Nemo's epic journey to find a new home 2Shorebird's beak inspires UT Arlington research on water collection 2
... Parkinson,s and Alzheimer,s is set to take a step ... analysis using automated 3D microscopy. An initiative ... the Eskitis Institute for Cellular and Molecular Biology, the ... of cells as complex as nerve cells in the ...
... study led by the University of North Carolina at Chapel ... 6 months in high-risk infants who later develop autism, compared ... a promising finding," said Jason J. Wolff, PhD, lead author ... Institute for Developmental Disabilities (CIDD). "At this point, it,s a ...
... at Oregon Health & Science University have ... supporting role actually are critically important for the growth ... has profound implications for the prevention and treatment of ... death in children aged one month to one year. ...
Cached Biology News:Brain-imaging differences evident at 6 months in infants who develop autism 2OHSU discovery may someday lead to prevention and treatment of sudden infant death syndrome 2
... The pWEB::TNC™ Deletion Cosmid Cloning Kit ... days, a complete and unbiased primary cosmid ... in making nested deletion sublibraries. High efficiency ... and highly reproducible kit protocols. First, genomic ...
... Disposable. Virgin, optically clear polystyrene with ... alphanumeric coordinates for cell counting. 100% ... is a new product number, created ... If showing no availability yet, please ...
Mouse monoclonal antibody raised against a partial recombinant AATK. NCBI Entrez Gene ID = AATK...
Packaging: package with 500 l Patent/trademark/license (electronic): (r) Registered trademark of Molecular Probes...
Biology Products: